News19 hours ago
Sumitomo Pharma Oncology, Inc. Presents Updated Preliminary Data from Phase 1/2 Clinical Study Evaluating Investigational Agent TP-3654 in Patients with Myelofibrosis at European Hematology Association 2023 Hybrid Congress
CAMBRIDGE, Mass., June 9, 2023 /PRNewswire/ — Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics, today presented updated preliminary data from the...
